Beta Drugs Limited

NSEI:BETA 株式レポート

時価総額:₹16.1b

このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Beta Drugs 配当金

配当金 基準チェック /06

Beta Drugs配当金を支払った記録がありません。

主要情報

n/a

配当利回り

n/a

配当性向

業界平均利回り0.6%
次回配当支払日n/a
配当落ち日n/a
一株当たり配当金n/a
一株当たり利益₹37.90
配当利回り予想n/a

最近の配当金アップデート

更新なし

Recent updates

Does Beta Drugs (NSE:BETA) Deserve A Spot On Your Watchlist?

Aug 30
Does Beta Drugs (NSE:BETA) Deserve A Spot On Your Watchlist?

Investors Appear Satisfied With Beta Drugs Limited's (NSE:BETA) Prospects As Shares Rocket 27%

Aug 30
Investors Appear Satisfied With Beta Drugs Limited's (NSE:BETA) Prospects As Shares Rocket 27%

Earnings Tell The Story For Beta Drugs Limited (NSE:BETA) As Its Stock Soars 29%

Dec 23
Earnings Tell The Story For Beta Drugs Limited (NSE:BETA) As Its Stock Soars 29%

Does Beta Drugs (NSE:BETA) Deserve A Spot On Your Watchlist?

Dec 11
Does Beta Drugs (NSE:BETA) Deserve A Spot On Your Watchlist?

These 4 Measures Indicate That Beta Drugs (NSE:BETA) Is Using Debt Reasonably Well

Jul 29
These 4 Measures Indicate That Beta Drugs (NSE:BETA) Is Using Debt Reasonably Well

Here's Why We Think Beta Drugs (NSE:BETA) Is Well Worth Watching

Jun 17
Here's Why We Think Beta Drugs (NSE:BETA) Is Well Worth Watching

Here's Why I Think Beta Drugs (NSE:BETA) Might Deserve Your Attention Today

Feb 21
Here's Why I Think Beta Drugs (NSE:BETA) Might Deserve Your Attention Today

Beta Drugs (NSE:BETA) Seems To Use Debt Quite Sensibly

Dec 20
Beta Drugs (NSE:BETA) Seems To Use Debt Quite Sensibly

With EPS Growth And More, Beta Drugs (NSE:BETA) Is Interesting

Nov 21
With EPS Growth And More, Beta Drugs (NSE:BETA) Is Interesting

These 4 Measures Indicate That Beta Drugs (NSE:BETA) Is Using Debt Reasonably Well

Sep 02
These 4 Measures Indicate That Beta Drugs (NSE:BETA) Is Using Debt Reasonably Well

Beta Drugs (NSE:BETA) Seems To Use Debt Quite Sensibly

May 20
Beta Drugs (NSE:BETA) Seems To Use Debt Quite Sensibly

Is Beta Drugs (NSE:BETA) A Risky Investment?

Jan 29
Is Beta Drugs (NSE:BETA) A Risky Investment?

Is Beta Drugs Limited's (NSE:BETA) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?

Dec 25
Is Beta Drugs Limited's (NSE:BETA) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?

Chairman & MD Vijay Batra Just Bought A Handful Of Shares In Beta Drugs Limited (NSE:BETA)

Nov 20
Chairman & MD Vijay Batra Just Bought A Handful Of Shares In Beta Drugs Limited (NSE:BETA)

決済の安定と成長

配当データの取得

安定した配当: BETAの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。

増加する配当: BETAの配当金が増加しているかどうかを判断するにはデータが不十分です。


配当利回り対市場

Beta Drugs 配当利回り対市場
BETA 配当利回りは市場と比べてどうか?
セグメント配当利回り
会社 (BETA)n/a
市場下位25% (IN)0.2%
市場トップ25% (IN)1.0%
業界平均 (Pharmaceuticals)0.6%
アナリスト予想 (BETA) (最長3年)n/a

注目すべき配当: BETAは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。

高配当: BETAは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。


株主への利益配当

収益カバレッジ: BETAの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。


株主配当金

キャッシュフローカバレッジ: BETAが配当金を報告していないため、配当金の持続可能性を計算できません。


高配当企業の発掘